FORT MYERS, Fla. (AP) — FORT MYERS, Fla. (AP) — NeoGenomics Inc. (NEO) on Tuesday reported a loss of $15.3 million in its fourth quarter.
On a per-share basis, the Fort Myers, Florida-based company said it had a loss of 12 cents. Earnings, adjusted for amortization costs and stock option expense, were 4 cents per share.
The results surpassed Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for earnings of 2 cents per share.
The operator of cancer-focused testing laboratories posted revenue of $172 million in the period, which fell short of Street forecasts. Seven analysts surveyed by Zacks expected $173.6 million.
For the year, the company reported a loss of $78.7 million, or 62 cents per share. Revenue was reported as $660.6 million.
NeoGenomics expects full-year revenue in the range of $735 million to $745 million.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on NEO at https://www.zacks.com/ap/NEO
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.